Trial reportPediatric research2016
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood.
Trial report in Pediatric research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial on the Safety and Efficacy of L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis: A Proof of Concept
A Randomized, Double-blind, Controlled Study to Evaluate the Gut Health, Feces Characteristics and Growth of Healthy Term Infants Fed With a New Infant Organic Formula
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Safety of One of the Most Commonly Used Probiotic Strains: Systematic Review and Meta-analysis of Reported Adverse Events.Probiotics and antimicrobial proteins · 2026Pooled it
- Comparative efficacy of different probiotic strains and preparations for prevention of acute otitis media in children: a systematic review and network meta-analysis.Frontiers in nutrition · 2026Pooled it
- Probiotics for preventing acute upper respiratory tract infections.The Cochrane database of systematic reviews · 2022Pooled it
- Probiotics for preventing acute otitis media in children.The Cochrane database of systematic reviews · 2019Pooled it
- Pooled it
- Lactoferrin combined withFrontiers in pediatrics · 2026Trial
- Trial
- Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Isolation and Characterization of Bifidobacterium longum A1, an Isolate from Faeces of an Exclusively Breast-fed Infant with Probiotic Potential.Probiotics and antimicrobial proteins · 2026Article
- Comparative Immunomodulatory Profiles ofJournal of microbiology and biotechnology · 2026Article
- Efficacy of probiotic-supplemented formula in treating chronic diarrhea in children aged 6-43 months: evidence based on a randomized controlled trial.Gut pathogens · 2026Article
- Hidden connection: Impact of the gut microbiota on respiratory diseases in children (Review).Molecular medicine reports · 2026Review
- Health benefits ofFrontiers in microbiology · 2026Review
- Functional Food Ingredients Enhancing Immune Health.International journal of molecular sciences · 2025Review
- Probiotic, Prebiotic, and Synbiotic Supplementation for the Prevention and Treatment of Acute Otitis Media: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2025Review
- Advancements related to probiotics for preventing and treating recurrent respiratory tract infections in children.Frontiers in pediatrics · 2025Review
- Polydextrose-driven gut microbiota modulation from synbiotic yogurt intake simulated in theFrontiers in nutrition · 2025Article
- The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.Journal of clinical medicine · 2023Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpecific probiotic bacteria have proven to be effective in the prevention and treatment of infectious diseases in early life in at-risk populations. The impact of administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy children.
methodsIn this double-blind, placebo-controlled study, 109 1-mo-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n = 55) or a placebo (n = 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 y with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications, and all signs and symptoms of acute infections were registered in diaries by parents and in questionnaires by trained professionals.
resultsThe infants receiving BB-12 were reported to have experienced fewer respiratory tract infections (RTIs; 87 vs. 100%; risk ratio: 0.87; 95% confidence interval: 0.76, 1.00; P = 0.033) than the controls. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media, or fever. The baseline characteristics of the two groups were similar, as was the duration of breastfeeding.
conclusionAdministration of BB-12 in early childhood may reduce RTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.